This article is more than 5 years old. Information may no longer be current.
New P2Y12 inhibitors decreased mortality, major adverse cardiac events after PCI vs. clopidogrel
Bellemain-Appaix A. J Am Coll Cardiol. 2010;doi:10.1016/j.jacc.2010.07.012.
Click Here to Manage Email Alerts
New P2Y12 inhibitors, including prasugrel, ticagrelor, cangrelor and elinogrel, when compared with clopidogrel decreased death and major adverse cardiac events after percutaneous coronary intervention, according to data from a new study featured in the Journal of the American College of Cardiology.
Researchers utilized Medline and Cochrane databases to search for randomized, placebo-controlled trials comparing new P2Y12 antagonists with clopidogrel (Plavix, Sanofi-Aventis) in PCI between 1980 and 2010. The final analysis included eight studies (n=48,599) in which 94% of patients had acute coronary syndrome and 84% of patients underwent PCI.
Of the study population, 50.8% (n=24,697) of patients received a new P2Y12 inhibitor. New inhibitors vs. clopidogrel decreased death (2.75% vs. 3.35%; OR=0.83; 95% CI, 0.75-0.92), CV death (2.95% vs. 3.61%; OR=0.82; 95% CI, 0.72-0.92), and major adverse coronary events (8.81% vs. 10.33%; OR=0.86; 95% CI, 0.8-0.93). MI, stent thrombosis and target vessel revascularization were all also significantly decreased; however there was an increase in thrombolysis in MI major bleeding (1.78% vs. 1.43%; OR=1.21; 95% CI, 1.05-1.4).
“The main finding of the present meta-analysis is the decrease in mortality observed with these new P2Y12 inhibitors compared with clopidogrel when used in patients treated with PCI,” researchers concluded. “The net benefit is particularly marked in PCI for STEMI patients, in which there is no significant increase in major bleeding when compared with clopidogrel.”
 |
Follow CardiologyToday.com on Twitter. |